Furthermore, according to results from experiments involving the CCL20 mAb, CCL20-neutralizing antibodies that suppress skin inflammation might exhibit efficacy in the future as a treatment for ACD. The gene discussed is CCL20; the disease is granular corneal dystrophy type II.